Cargando…

Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator

OBJECTIVE: Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [(123)I]I-metaiodobenzylguanidine (MIBG) enables assessment of the cardiac adrenergic nervous system. Tomographic imaging of the heart is expected to be superior to planar imagi...

Descripción completa

Detalles Bibliográficos
Autores principales: Teresińska, Anna, Woźniak, Olgierd, Maciąg, Aleksander, Wnuk, Jacek, Jezierski, Jarosław, Fronczak, Aneta, Biernacka, Elżbieta Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285320/
https://www.ncbi.nlm.nih.gov/pubmed/34023989
http://dx.doi.org/10.1007/s12149-021-01628-1
_version_ 1783723537221025792
author Teresińska, Anna
Woźniak, Olgierd
Maciąg, Aleksander
Wnuk, Jacek
Jezierski, Jarosław
Fronczak, Aneta
Biernacka, Elżbieta Katarzyna
author_facet Teresińska, Anna
Woźniak, Olgierd
Maciąg, Aleksander
Wnuk, Jacek
Jezierski, Jarosław
Fronczak, Aneta
Biernacka, Elżbieta Katarzyna
author_sort Teresińska, Anna
collection PubMed
description OBJECTIVE: Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [(123)I]I-metaiodobenzylguanidine (MIBG) enables assessment of the cardiac adrenergic nervous system. Tomographic imaging of the heart is expected to be superior to planar imaging. This study aimed to determine the quality and utility of MIBG SPECT in the assessment of cardiac innervation in postinfarction HF patients without DM, qualified for implantable cardioverter defibrillator (ICD) in primary prevention of sudden cardiac death. METHODS: Consecutive patients receiving an ICD on the basis of contemporary guidelines were prospectively included. Planar MIBG studies were followed by SPECT. The essential analysis was based on visual assessment of the quality of SPECT images (“high”, “low” or “unacceptable”). The variables used in the further analysis were late summed defect score for SPECT images and heart-to-mediastinum rate for planar images. MIBG images were assessed independently by two experienced readers. RESULTS: Fifty postinfarction nondiabetic HF subjects were enrolled. In 13 patients (26%), the assessment of SPECT studies was impossible. In addition, in 13 of 37 patients who underwent semiquantitative SPECT evaluation, the assessment was equivocal. Altogether, in 26/50 patients (52%, 95% confidence interval 38–65%), the quality of SPECT images was unacceptable or low and was limited by low MIBG cardiac uptake and by comparatively high, interfering MIBG uptake in the neighboring structures (primarily, in the lungs). CONCLUSIONS: The utility of MIBG SPECT imaging, at least with conventional imaging protocols, in the qualification of postinfarction HF patients for ICD, is limited. In approximately half of the postinfarction HF patients, SPECT assessment of cardiac innervation can be impossible or equivocal, even without additional damage from diabetic cardiac neuropathy. The criteria predisposing the patient to good-quality MIBG SPECT are: high values of LVEF from the range characterizing the patients qualified to ICD (i.e., close to 35%) and left lung uptake intensity in planar images comparable to or lower than heart uptake.
format Online
Article
Text
id pubmed-8285320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-82853202021-07-20 Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator Teresińska, Anna Woźniak, Olgierd Maciąg, Aleksander Wnuk, Jacek Jezierski, Jarosław Fronczak, Aneta Biernacka, Elżbieta Katarzyna Ann Nucl Med Original Article OBJECTIVE: Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [(123)I]I-metaiodobenzylguanidine (MIBG) enables assessment of the cardiac adrenergic nervous system. Tomographic imaging of the heart is expected to be superior to planar imaging. This study aimed to determine the quality and utility of MIBG SPECT in the assessment of cardiac innervation in postinfarction HF patients without DM, qualified for implantable cardioverter defibrillator (ICD) in primary prevention of sudden cardiac death. METHODS: Consecutive patients receiving an ICD on the basis of contemporary guidelines were prospectively included. Planar MIBG studies were followed by SPECT. The essential analysis was based on visual assessment of the quality of SPECT images (“high”, “low” or “unacceptable”). The variables used in the further analysis were late summed defect score for SPECT images and heart-to-mediastinum rate for planar images. MIBG images were assessed independently by two experienced readers. RESULTS: Fifty postinfarction nondiabetic HF subjects were enrolled. In 13 patients (26%), the assessment of SPECT studies was impossible. In addition, in 13 of 37 patients who underwent semiquantitative SPECT evaluation, the assessment was equivocal. Altogether, in 26/50 patients (52%, 95% confidence interval 38–65%), the quality of SPECT images was unacceptable or low and was limited by low MIBG cardiac uptake and by comparatively high, interfering MIBG uptake in the neighboring structures (primarily, in the lungs). CONCLUSIONS: The utility of MIBG SPECT imaging, at least with conventional imaging protocols, in the qualification of postinfarction HF patients for ICD, is limited. In approximately half of the postinfarction HF patients, SPECT assessment of cardiac innervation can be impossible or equivocal, even without additional damage from diabetic cardiac neuropathy. The criteria predisposing the patient to good-quality MIBG SPECT are: high values of LVEF from the range characterizing the patients qualified to ICD (i.e., close to 35%) and left lung uptake intensity in planar images comparable to or lower than heart uptake. Springer Singapore 2021-05-23 2021 /pmc/articles/PMC8285320/ /pubmed/34023989 http://dx.doi.org/10.1007/s12149-021-01628-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Teresińska, Anna
Woźniak, Olgierd
Maciąg, Aleksander
Wnuk, Jacek
Jezierski, Jarosław
Fronczak, Aneta
Biernacka, Elżbieta Katarzyna
Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title_full Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title_fullStr Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title_full_unstemmed Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title_short Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
title_sort quality and utility of [(123)i]i-metaiodobenzylguanidine cardiac spect imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285320/
https://www.ncbi.nlm.nih.gov/pubmed/34023989
http://dx.doi.org/10.1007/s12149-021-01628-1
work_keys_str_mv AT teresinskaanna qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT wozniakolgierd qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT maciagaleksander qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT wnukjacek qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT jezierskijarosław qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT fronczakaneta qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator
AT biernackaelzbietakatarzyna qualityandutilityof123iimetaiodobenzylguanidinecardiacspectimaginginnondiabeticpostinfarctionheartfailurepatientsqualifiedforimplantablecardioverterdefibrillator